About InVivoSIM anti-human AXL (Tilvestamab Biosimilar) This non-therapeutic biosimilar antibody utilizes the same variable regions as the therapeutic antibody Tilvestamab making it ideal for research use. Tilvestamab targets the AXL receptor tyrosine kinase, a member of the TAM (Tyro3, AXL, Mer) family. AXL is overexpressed in various malignancies, including renal cell carcinoma, non-small cell lung cancer, pancreatic cancer, and triple-negative breast cancer, and is associated with tumor progression, metastasis, and resistance to therapy. By binding to the extracellular domain of AXL, Tilvestamab inhibits the interaction with its ligand Gas6, thereby blocking downstream signaling pathways such as PI3K/AKT and MAPK/ERK. This blockade results in the suppression of tumor cell proliferation, migration, and survival. Preclinical studies have demonstrated that Tilvestamab effectively reduces AXL activation and downstream signaling, leading to decreased tumor growth in vivo. This biosimilar antibody serves as a valuable tool for studying AXL-mediated signaling, tumor biology, and the development of AXL-targeted therapies. InVivoSIM anti-human AXL (Tilvestamab Biosimilar) Specifications IsotypeHuman IgG1, κ Recommended Isotype Control(s)RecombiMAb human IgG1 isotype control, anti-hen egg lysozyme Recommended Dilution BufferInVivoPure pH 7.0 Dilution Buffer ImmunogenHuman AXL Reported ApplicationsFunctional assays Flow cytometry Western blot ELISA in vivo studies using xenograft models FormulationPBS, pH 7.0 Contains no stabilizers or preservatives Endotoxin<0.5EU/mg (<0.0005EU/μg) Determined by LAL gel clotting assay Aggregation<5% Determined by SEC Purity>95% Determined by SDS-PAGE Sterility0.2 μm filtration ProductionPurified from cell culture supernatant in an animal-free facility PurificationProtein A Molecular Weight150 kDa StorageThe antibody solution should be stored at the stock concentration at 4°C. Do not freeze.
